secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001493152-25-019315
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025
--------------------------------------------------------------------------------

- Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.
- Presented at AACR-NCI-EORTC Molecular Targets Conference in Boston.
- No specific efficacy or safety data disclosed in the 8-K filing.
- Company provided forward-looking statements caution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/0001493152-25-019315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019315/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer